Skip to main content
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. — Investor Relations & Filings

Ticker · SGMT ISIN · US7867001049 LEI · 2549002OT2F8BV0VPD02 US Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2024-05-08 Director's Dealing
Country US United States of America
Listing US SGMT

About Sagimet Biosciences Inc.

https://sagimet.com/

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company that develops novel fatty acid synthase (FASN) inhibitors. These therapeutics are designed to target dysfunctional metabolic and fibrotic pathways resulting from the overproduction of the fatty acid, palmitate. The company's lead product candidate is denifanstat, and its pipeline includes TVB-3567. Sagimet is exploring the application of its FASN inhibitors in treating diseases where dysregulation of fatty acid metabolism plays a key role, such as metabolic dysfunction-associated steatohepatitis (MASH), acne, and select forms of cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2024-05-08 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content specifically details the appointment of a new Chief Financial Officer, including biographical information, employment terms, and equity grants. This corresponds to an announcement of changes in senior management. There are no financial statements or detailed financial results, so it is not an Annual Report, Interim Report, or Earnings Release. The document is not a proxy statement, voting results, or legal proceeding. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (8311 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2024-05-06 English
ARS
Annual Report
2024-04-18 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about the election of directors, ratification of auditors, and instructions for voting. It explicitly states it is an overview of proxy materials and provides links to the full proxy statement and annual report. The document is 3472 characters long, which is relatively short and primarily serves as a notice and summary for shareholders to access the full proxy materials. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings. It is not the full Annual Report or the full Proxy Statement itself, but additional proxy materials. Therefore, the correct classification is PSI with high confidence.
2024-04-18 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-18 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-04-04 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.